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The development of sensitive assays for stable
markers of activated coagulation aznd fibrinolysis
has provided new insight into the pathophysiolo-
gy of acute deep venous thrombosis (DVT) and
may have some role in its diagnosis. Although the
activated enzymes of coagulation and fibrinolysis
are evanescent, measurable byproducts of zymo-
gen activation include D-dimer fibrin degradation
products formed by the action of plasmin on
cross-linked fibrin; prothrombin fragment 1+2 (F
1+2) generated by factor Xa in the cleavage of pro-
thrombin to thrombin; fibrinopeptide A formed in
the thrombin-mediated conversion of fibrinogen
to fibrin; and thrombin-antithrombin complex
formed by the combination of thrombin with its
primary inhibitor.1,2 Among these, F 1+2, fib-
rinopeptide A, and thrombin-antithrombin com-
plex similarly reflect the degree of thrombin acti-
vation, whereas D-dimer reflects fibrinolytic activ-
ity and the presence of intravascular thrombus.
The initial changes in these markers after throm-
bosis and treatment have been described,3-5 and
plasma D-dimer levels have been incorporated into
some diagnostic algorithms.6,7 However, the long-
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term changes occurring in these markers have not
been examined in detail.
The evolution of these markers over time is crit-
ical in their application to recurrent venous throm-
bosis, which remains a fundamental challenge in the
management of DVT. Although the adequacy of ini-
tial anticoagulation appears to be critical in prevent-
ing recurrent thrombosis,8 the ability to identify
subgroups at particular risk for such events is limit-
ed. This is especially important for thrombosis iso-
lated to the calf veins because treatment is primarily
based on the risk of proximal propagation. Because
the development of recurrent DVT is presumably
determined by the relative balance between coagula-
tion and fibrinolysis, these markers may have some
utility in identifying patients at highest risk.
Changes in these markers may also be relevant to
the diagnosis of recurrent DVT. Although venous
duplex ultrasonography canning is now the study of
choice for the initial diagnosis of DVT, its limita-
tions in the diagnosis of recurrent DVT are well rec-
ognized. Ultrasound scan interpretation in this set-
ting may be limited by variable degrees of residual
occlusion, partial recanalization, intimal thickening,
and collateral formation. Results of compression
ultrasound studies may remain abnormal in 27% to
70% of patients after 1 year.9-12 Favorable reports
regarding the use of D-dimer in the initial diagnosis
suggest that it may also have a role in the diagnosis
of recurrent DVT.
The purpose of this study was therefore to eval-
uate the initial determinants of quantitative D-dimer
and F 1+2 levels, to document changes in these lev-
els after initial presentation, and to evaluate their
utility in the diagnosis of recurrent DVT.
METHODS
All patients presenting to the University of
Washington Medical Center with an acute DVT
confirmed by duplex ultrasonography were asked to
participate in a long-term study of the natural histo-
ry of DVT. Patients with a limited life expectancy
receiving prophylactic or therapeutic doses of anti-
coagulants before enrollment or having a residence
or medical condition preventing their return were
excluded from enrollment. All treatment decisions
were made by the patient’s primary physician. The
Human Subjects Committee at the University of
Washington approved the study protocol, and
informed consent was obtained from all subjects.
Immediately after enrollment and before admin-
istration of anticoagulants, blood was drawn for
Fig 1. Correlation between extent of thrombus (SVS/NA-ISCVS thrombus score) at presentation and
initial plasma D-dimer level (R = 0.39, P = .003).
Table I. Thrombotic risk factors
Risk factor No. (%)
Age > 40 y 44 (72.1)
Malignancy 23 (37.7)
> 3 day’s immobilization 18 (29.5)
Estrogen therapy 12 (19.7)
Surgery 11 (18.0)
Cardiac disease 6 (9.8)
Prolonged (> 6 h) travel 6 (9.8)
Limb trauma 6 (9.8)
Family history 5 (8.2)
Previous DVT 3 (4.9)
Pregnant 2 (3.3)
Known prothrombotic state 1 (1.6)
Obese 0 (0)
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determination of plasma D-dimer cross-linked fibrin
degradation products and prothrombin fragment
1+2 levels. A complete medical history was
obtained, and thrombotic risk scores were calculated
according to the Society for Vascular Surgery and
the North American Chapter of the International
Society for Cardiovascular Surgery (SVS/ISCVS)
reporting standards in venous disease.13 Patients
were then requested to return for follow-up visits at
intervals of 3, 7, and 14 days and 1, 3, 6, 9, and 12
months after initial presentation. At each visit,
patients were questioned regarding limb symptoms,
their lower extremities were examined, and duplex
ultrasonography of the lower extremity veins was
performed. Blood was also drawn for determination
of plasma D-dimer and F 1+2 levels.
Duplex scanning of both lower extremities was
performed in the 15-degree reverse Trendelenburg
position with an Ultramark 9 instrument (Advanced
Technology Laboratories, Bothell, Wash). A phased
array 3-2 MHz transducer was used for the inferior
vena cava and iliac segments, and a linear array 7-4
MHz transducer was used for the veins below the
inguinal ligament. All superficial and deep venous
segments from the inferior vena cava to the calf veins
were assessed for the presence of thrombus at each
visit. Individual venous segments were defined as
patent, partially occluded, or completely occluded on
the basis of established B mode and Doppler crite-
ria,14 and the extent of thrombosis was determined
on a 24-point scale according to the reporting stan-
dards in venous disease.13 Recurrent thrombotic
events were defined by ultrasound criteria to include
propagation of thrombus to initially uninvolved
venous segments, progression of nonocclusive
thrombus within a segment to complete occlusion,
rethrombosis of a partially or completely recanalized
segment, or new thrombus within an initially unin-
volved contralateral limb. The events were further
defined as occurring early (≤ 30 days) or late (> 30
days) after initial presentation.
Blood for all laboratory studies was drawn with a
two-tube technique, discarding the first 4 to 5 mL.
Samples were anticoagulated by the addition of 4.5 mL
of whole blood to 0.5 mL of 0.105 mol/L sodium cit-
rate and centrifuged at 2000g for 15 minutes at room
temperature. Citrate plasma was removed and frozen at
–70°C before analysis. Quantitative D-dimer levels
were determined with an enzyme-linked immunosor-
bent assay (ELISA), as previously described.15 For D-
dimer, the normal range (< 400 ng/mL) was defined
as identical to that used for the exclusion of DVT in the
clinical laboratory with a rapid D-dimer assay (sensitiv-
ity, 94.6%; specificity, 35%).16 F 1+2 (normal, 0.4-1.1
nmol/L) was similarly assessed with an ELISA method
from Behring Inc.17
Because most variables were not uniformly dis-
tributed, all data are reported as the median and
interquartile range (IQR, 25th to 75th percentile).
Bivariate analysis was performed with linear regres-
sion or the Mann-Whitney test for continuous vari-
ables and the χ2 test for categoric variables.
Determinants significant at a P value of .10 or less
were entered into multivariate stepwise regression
and logistic regression models. The sensitivity and
specificity of various D-dimer and F 1+2 levels in
Fig 2. Correlation between extent of thrombus (SVS/NA-ISCVS thrombus score) at presentation and
initial plasma F 1+2 level (R = 0.28, P = .08).
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predicting recurrent thrombotic events were evalu-
ated with receiver-operator characteristic (ROC)
analysis with Rockit statistical software (Department
of Radiology, University of Chicago, Chicago, Ill).
Sensitivity for the diagnosis of recurrent thrombosis
was defined as true-positive results in patients with
recurrence divided by total patients with recurrence,
and specificity was defined as true-negative results in
patients without recurrence divided by total patients
without recurrence. Statistical significance was
defined at a P value of .05 or less.
RESULTS
Between October 1997 and September 1999, 61
patients with an acute DVT were enrolled and fol-
lowed up for a median of 266 days (IQR, 91.5-364
days). Subjects included 30 (49.2%) women and 31
(50.8%) men with a median age of 54.6 years (IQR,
39.5-64.3 years). The median SVS/NA-ISCVS risk
score among these patients was 4 (IQR, 2-6), with a
median of 2.0 (IQR, 1.5-3.0) risk factors per patient
(Table I). Thrombosis was bilateral in nine (14.8%)
patients and unilateral in the right and left limbs in
22 (36.1%) and 30 (49.2%) patients, respectively.
These included 34 (55.7%) proximal thrombi and
27 (44.3%) isolated calf vein thrombi with a median
thrombus score of 3.0 (IQR, 2.0-7.0). Of the 57
patients completing early follow-up, 42 (73.7%)
were initially treated with intravenous unfractionat-
ed or subcutaneous low-molecular-weight heparin, 2
(3.5%) were treated with warfarin alone, and 13
(22.8%) were not treated with anticoagulants.
Among those treated with unfractionated heparin,
the median duration of treatment was 5.0 days
(IQR, 4.0-9.5 days), and a median of 80% (IQR, 50-
100) of partial thromboplastin times was within the
therapeutic range.
Fifty-five patients had blood samples obtained at
the time of presentation. Among these patients,
median D-dimer and F 1+2 levels were 2320
ng/mL (IQR, 1364-5733 ng/mL) and 2.2 nmol/L
(IQR, 1.7-3.5 nmol/L), respectively. D-dimer and F
1+2 levels were elevated in 51 (92.7%) and 52
(94.5%) patients, respectively. Initial D-dimer levels
were significantly related to total thrombus score (P
= .003), whereas F 1+2 levels were only marginally
related to the extent of thrombus (P = .08, Figs 1
and 2). In comparison with those with proximal
Table II. Follow-up D-dimer and F 1+2 levels
Follow-up D-dimer F 1+2
interval No. Median (IQR) No. ≥ 400* No. Median (IQR) No. ≥ 1.1*
Day 0 55 2320 (1364-5733) 51 (92.7%) 55 2.2 (1.7-3.5) 52 (94.5%)
Day 3 50 2033 (1248-3252) 47 (94%) 51 1.5 (1.0-2.2) 34 (66.7%)
Day 7 50 1719 (1008-3444) 46 (92%) 50 1.2 (0.6-2.0) 27 (54%)
Day 14 46 1034 (475-2749) 37 (80.4%) 48 0.5 (0.3-1.7) 21 (43.8%)
Day 30 46 660 (272-1362) 31 (67.4%) 46 0.7 (0.4-1.6) 20 (43.5%)
3 mo 43 440 (208-999) 26 (60.5%) 44 0.6 (0.3-1.2) 14 (31.8%)
6 mo 33 407 (209-861) 18 (54.5%) 34 0.6 (0.3-1.2) 9 (26.5%)
9 mo 27 534 (356-1184) 18 (66.7%) 27 1.0 (0.5-1.3) 11 (40.7%)
1 y 20 646 (383-1542) 14 (70%) 20 0.9 (0.4-1.3) 7 (35%)
*Number of patients with values above the normal range.
Table III. D-dimer and F 1+2 levels at 6 months’ follow-up
D-Dimer F 1+2
< 400 ng/mL ≥ 400 ng/mL < 1.1 nmol/L ≥ 1.1 nmol/L
(n = 15)* (n = 18)* P value (n = 24)* (n = 9)* P value
6-mo thrombus score 2.0 (0.0-3.0) 1.0 (0.75-2.25) .57 1.0 (1.0-3.0) 1.0 (0-3.5) .68
Initial thrombus score 2.0 (2.0-4.0) 2.0 (1.0-7.0) .85 2.5 (2.0-6.75) 2.0 (1.0-4.5) .33
Age (y) 48 (29-64) 60 (51-73) .05 51 (33-63) 60 (56-75) .03
Risk score 2.0 (1.0-3.0) 4.5 (2.0-6.0) .01 2.0 (2.0-4.5) 4.0 (3.0-5.5) .09
Risk factors 2.0 (1.0-2.0) 3.0 (1.75-3.25) .009 2.0 (1.0-3.0) 3.0 (2.5-3.5) .03
Irreversible factors† 1.0 (1.0-1.0) 2.0 (1.0-2.0) .04 1.0 (0.25-2.0) 2.0 (1.0-2.0) .07
*Median (IQR).
†Number of irreversible risk factors, including age over 40 years, malignancy, cardiac disease, previous history of DVT, family history of
thrombosis, known prothrombotic state, and obesity.
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thrombosis, patients with isolated calf vein throm-
bosis had significantly lower D-dimer (1967 ng/mL
[IQR, 1128-3213 ng/mL] vs 3356 ng/mL [IQR,
2016-8469 ng/mL]; P = .02) and F 1+2 (2.0
nmol/L [IQR, 1.5-2.4 nmol/L] vs 2.7 nmol/L
[IQR, 2.0-4.4 nmol/L]; P = .004) levels. A history
of prolonged travel was the only thrombotic risk fac-
tor related to initial D-dimer values, with median
levels being higher among those without a travel his-
tory (2745 ng/mL [IQR, 1562.5-6679.5 ng/mL]
vs 1462.5 ng/mL [IQR, 271.8-2240.5 ng/mL]; P
= .03). A history of cardiac disease (3.6 nmol/L
[IQR, 2.23-4.68 nmol/L] vs 2.1 nmol/L [IQR,
1.6-3.1 nmol/L]; P = .05) was associated with high-
er initial F 1+2 levels, whereas recent limb trauma
(1.6 nmol/L [IQR, 0.75-1.85 nmol/L] vs 2.4
nmol/L [IQR, 1.8-3.73 nmol/L]; P = .001) was
associated with lower levels. However, in a multi-
variate analysis including extent of thrombosis, prox-
imal versus distal thrombosis, and risk factors,
thrombus score was the only significant predictor of
initial D-dimer levels (P = .003), whereas the pres-
ence of proximal thrombosis was the only significant
predictor of F 1+2 levels (P = .001).
Both D-dimer and F 1+2 levels decreased rapid-
ly after initial presentation. D-dimer levels at day 3
were independent of initial treatment, with median
levels among those treated with unfractionated or
low-molecular-weight heparin (2037 ng/mL [IQR,
1041-3376 ng/mL]) being similar to levels of those
who were untreated or treated with warfarin alone
(2028 ng/mL [IQR, 1693-2578 ng/mL]; P = .73).
However, median F 1+2 levels at day 3 were signif-
icantly lower among those treated with unfraction-
ated or low-molecular-weight heparin (1.1 nmol/L
[IQR, 0.8-2.0 nmol/L] vs 2.0 nmol/L [IQR, 1.8-
3.0 nmol/L]; P = .001). Median F 1+2 levels nor-
malized by 14 days, whereas median D-dimer levels
approached normal levels by 3 months (Table II).
However, after 1 year of follow-up, D-dimer and F
1+2 levels remained elevated in 70% and 35% of
patients, respectively.
In comparison with those with normal D-dimer
and F 1+2 levels, subjects with persistently elevated
levels at 6 months were significantly older and had
higher risk scores, greater numbers of thrombotic
risk factors, and more irreversible risk factors. In
contrast, extent of thrombosis both at presentation
and at the 6-month follow-up interval was not sig-
nificantly different from those in patients with nor-
Fig 3. Median D-dimer levels during follow-up stratified according to the presence of ultrasound
scan–defined recurrent thrombosis. Dashed line indicates diagnostic limit for acute DVT (≥ 400
ng/mL). Plasma levels at day 0 are significantly different (P = .002) between those with and without
subsequent recurrent events. Number of patients evaluated at each follow-up interval and the corre-
sponding IQR are shown.
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mal D-dimer and F 1+2 levels (Table III). Similar
trends were present for those with elevated levels at
1 year, although because of small patient numbers,
differences in risk score, number of risk factors, and
number of irreversible risk factors did not reach sta-
tistical significance.
Thirty-seven recurrent thrombotic events were
observed in 26 (43%) patients. Although clustered
early after presentation, recurrent thrombosis was
observed throughout the 1-year follow-up interval.
Fifteen (40.5%) events were observed within the first
3 days of follow-up, 14 (37.8%) between days 3 and
30, and 4 (10.8%) in each of the intervals between 1
and 6 months and 6 and 12 months. Neither throm-
bus score (P = .15) nor overall risk score (P = .35)
was significantly related to recurrent thrombotic
events. However, initial D-dimer (P = .002) and F
1+2 (P = .009) levels were significantly higher
among patients with recurrent thrombosis (Figs 3
and 4). In a logistic regression model, initial F 1+2
levels (P = .04) were more highly related to recur-
rent events than initial D-dimer levels (P = .33).
However, initial D-dimer levels performed slightly
better in the receiver-operator characteristic analysis.
In predicting recurrent thrombosis, an initial D-
dimer level of 2000 ng/mL or greater provided a
sensitivity of 87% and a specificity of 56.3%, where-
as F 1+2 levels of 2.0 nmol/L or greater had a sen-
sitivity of 82.6% and specificity of 43.8%. Similarly,
for thrombosis confined to the calf, a D-dimer level
of 2000 ng/mL or greater had a sensitivity and
specificity of 88.9% and 76.5% in predicting recur-
rent events, whereas F 1+2 levels of 2.0 nmol/L or
greater had a sensitivity of 66.7% and specificity of
52.9%. Among patients with isolated calf vein
thrombosis, recurrent thrombosis developed in 67%
of those with an initial D-dimer level of 2000
ng/mL or greater in comparison with 7% of those
with levels of less than 2000 ng/mL. For F 1+2,
recurrent thrombosis occurred in 43% of patients
with isolated calf vein thrombosis and an F 1+2 level
of 2.0 nmol/L or greater in comparison with 25% of
those with levels of less than 2.0 nmol/L.
Persistent D-dimer and F 1+2 elevations limited
the utility of the threshold values used for the initial
diagnosis of DVT. F 1+2 levels of 1.1 nmol/L or
greater had an overall sensitivity and specificity of
62.9% and 49.3%, respectively, for the diagnosis of
recurrent thrombotic events. If only early (≤ 30 days)
events were considered, sensitivity improved to 71.4%,
and specificity decreased to 39.6%. For the diagnosis of
late recurrence (> 30 days), the sensitivity was only
28.6%, with a specificity of 67.5%. For D-dimer levels,
different critical values could be selected on the basis
of the timing of recurrent thrombosis. For early recur-
rence, D-dimer levels of 1000 ng/mL or greater pro-
vided an optimal sensitivity and specificity of 89.3%
and 35.6%, respectively. Positive and negative predic-
tive values in this population were 15.1% and 96.3%,
respectively. For late recurrence, D-dimer levels of 500
ng/mL or greater provided a sensitivity of 100% and
specificity of 53.9%, with positive and negative predic-
tive values of 11.7% and 88.3%, respectively. In com-
parison with the value at the previous visit, the sensi-
tivity and specificity of an increase in D-dimer levels
were 35.7% and 59.7%, respectively, with a positive
and negative predictive value of 8.9% and 89.3% in this
population (Table IV). For interval increases in pro-
thrombin F 1+2 levels, sensitivity and specificity were
28.6% and 69.6%, respectively, with a positive and neg-
ative predictive value of 9.2% and 90.0% (Table V).
DISCUSSION
The development of specific assays for stable mark-
ers of activated coagulation and intravascular throm-
bus formation has provided new insight into the
pathophysiology of acute DVT. In contrast to the
measurement of zymogen levels and standard clotting
tests, these assays are able to detect low-level activation
Table IV. Interval D-dimer increases
Recurrent thrombosis
Yes No Total
Interval D-dimer increase Yes 10 102 112
No 18 151 169
Total 28 253 281
Table V. Interval F 1+2 increases
Recurrent thrombosis
Yes No Total
Interval F 1+2 increase Yes 8 79 87
No 20 181 201
Total 28 260 288
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of the coagulation system and localized thrombotic
events.1,2 Several thrombotic risk factors have been
associated with increased levels of thrombin activation
markers, confirming the importance of activated coag-
ulation in thrombogenesis. Increased levels of these
markers have been described in association with
advanced age,2,18 surgery,19 trauma,20 oral contracep-
tives,21,22 and malignancy.23
Elevated levels of these markers have also been
shown to be useful in excluding a diagnosis of acute
DVT. Although of variable sensitivity, the uniformly
low specificity of these tests requires confirmatory
testing of patients with positive results. D-dimer lev-
els appear to be more sensitive than the markers of
thrombin activation,1,3,4,16,24 an observation that
may reflect fluctuation in thrombin activity and the
longer half-life of D-dimer. In 11 published series of
symptomatic acute DVT, the average weighted sensi-
tivity and specificity of D-dimer determined with the
ELISA technique have been reported to be 96.8%
and 35.2%, respectively.25 Lower sensitivities of 47%
to 66% have been reported for F 1+2 levels.3,24
Although not a study of diagnostic accuracy, the
results of this study are consistent with these reports.
D-dimer and F 1+2 levels were elevated at the time of
presentation in 92.7% and 94.5% of patients, respec-
tively. However, this study further demonstrates that
initial D-dimer levels are most significantly related to
the extent of thrombosis, whereas F 1+2 levels are
more highly associated with the presence of proximal
thrombus. The relationship between D-dimer level
and thrombus extent most likely reflects the quantity
of thrombus susceptible to the action of plasmin. The
magnitude of the correlation between plasma D-
dimer level and thrombus extent determined by ultra-
sound (R = 0.39) is similar to that reported for veno-
graphically determined thrombus extent (R = 0.34-
0.36).3,26 Although statistically significant, this
relatively weak correlation suggests that fibrinolytic
differences between individuals may also be impor-
tant. The relationship between F 1+2 level and
thrombus location is more interesting because it
implies that thrombus confined to the calf veins is
associated with less extensive thrombin activation.
Although it is clear that most thrombi begin in the
calf veins,27,28 this observation further suggests that
isolated calf vein thrombi may differ pathophysiolog-
ically from proximal thrombi. That is, they are not
simply early thrombi that have yet to propagate, but
rather reflect a more limited prothrombotic state.
Fig 4. Median F 1+2 levels during follow-up stratified according to the presence of ultrasound
scan–defined recurrent thrombosis. Dashed line indicates upper limit of normal range (1.1 nmol/L).
Plasma levels at day 0 are significantly different (P = .009) between those with and without subsequent
recurrent events. Number of patients evaluated at each follow-up interval and the corresponding IQR
are shown.
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Although this was a small study, thrombotic risk
factors were not independently associated with ini-
tial D-dimer or F 1+2 levels. Patients having risk fac-
tors associated with underlying elevations of throm-
bin activation products might have been expected to
have higher levels of these markers after the devel-
opment of DVT. The finding that these risk factors
are not associated with increased F 1+2 levels after
thrombosis may reflect either the strong amplifica-
tion of the coagulation cascade associated with clin-
ical thrombosis29 or the existence of a thrombotic
threshold at which acute DVT occurs independent
of baseline prothrombin activation.30 The latter
would imply that a similar level of thrombin activity
is required for thrombosis to occur, regardless of the
underlying risk factors. A larger number of patients
with levels measured before thrombosis would be
required to substantiate this hypothesis.
Several studies have examined changes in plasma
coagulation and fibrinolytic markers during the first
10 days of treatment,3-5 but the long-term changes
after an episode of DVT have not been well charac-
terized. Although some have found markers of
thrombin activation to normalize early after effective
treatment is instituted,4 most have found these mark-
ers to rapidly decrease, but not fully normalize, dur-
ing the first 10 days. Consistent with these observa-
tions, median D-dimer and F 1+2 levels in this study
rapidly declined after initial presentation. However,
despite this overall trend, these markers remained
abnormal for prolonged periods in a substantial num-
ber of patients. Although median F 1+2 values
returned to normal with the first 14 days, a pro-
thrombotic state, implied by elevated F 1+2 levels,
persisted in 27% to 44% of the patients evaluated
between 14 days and 1 year after thrombosis. This
was associated with a 43% incidence of ultrasound-
documented recurrent events. Consistent with a per-
sistent thrombus load, median D-dimer levels
approached normal by 3 months but remained ele-
vated throughout the first year in most patients. The
initial decrease in both markers was likely caused by a
rapid reduction in thrombin activity and the genera-
tion of new lysable fibrin, whereas the slower subse-
quent decline in D-dimer levels reflects the decreased
susceptibility of older thrombus to lysis.4 In contrast
to the initial levels, persistent elevations of both
markers were related to age and thrombotic risk,
which is consistent with ongoing hypercoagulability
and perhaps fibrin generation.
These observations have important implications
for the diagnosis of recurrent thrombosis. Fluctu-
ations in the levels of both markers make interval
increases in their levels of little diagnostic significance.
This contrasts with other small series suggesting an
increase in D-dimer levels of greater than 3 µg/mL
within the first 10 days to be a specific but insensitive
indicator of recurrent thrombosis.3 Furthermore, per-
sistent elevations will a priori reduce the specificity
and positive predictive value of these markers with the
criteria used for the initial diagnosis of DVT. Despite
these limitations, these tests may still have some utili-
ty in the diagnosis of recurrent DVT if sensitivity and
negative predictive value are sufficiently high.
Although most patients with elevated levels will not
have recurrent thrombosis (low positive predictive
value), low levels can exclude the diagnosis. This is
particularly true for D-dimer, where values of 1000
ng/mL or greater and 500 ng/mL or greater had
sensitivities of 89% and 100%, respectively, in detect-
ing early and late recurrences. As in the initial diag-
nosis of DVT, the low specificities and positive pre-
dictive value of these measurements limit their utility
to the exclusion, rather than the confirmation, of
recurrent disease. However, given the potential limi-
tations of other diagnostic modalities, including
venous duplex ultrasonography and venography, D-
dimer measurements may have some clinical value in
this setting. A D-dimer level of less than 500 ng/mL
in a patient with pain, swelling, and a duplex scan
demonstrating thrombus of indeterminate age 9
months after presentation could potentially allow the
patient to be spared the risk and inconvenience of
reinstituting anticoagulation.
Perhaps of greater value is the relationship
between initial levels of these markers and subse-
quent recurrent events. Although specificity was
again limited, D-dimer levels of 2000 ng/mL or
greater and F 1+2 levels of 2.0 nmol/L or greater
had sensitivities of 87% and 83%, respectively, in pre-
dicting recurrent thrombotic events. This may have
important implications, particularly for the manage-
ment of isolated calf vein thrombosis. Although
management remains controversial, anticoagulant
treatment of these thrombi is often recommended
on the basis of the observation that approximately
20% will propagate to a more proximal level.31,32 In
this regard an initial D-dimer level of 2000 ng/mL
or greater was highly associated with the aggregate
outcome of recurrent thrombosis, which included
proximal propagation. Two thirds of patients with
isolated calf vein thrombosis and a D-dimer level of
2000 ng/mL or greater had recurrent thrombosis in
comparison with less than 10% of those with lower
levels. Although larger confirmatory studies are
obviously required, patients with initial D-dimer lev-
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els of 2000 ng/mL or greater are perhaps most
appropriately treated with standard anticoagulation,
whereas serial noninvasive follow-up may be an
option in those with levels below 2000 ng/mL.
Other uses of these markers remain speculative,
but they may have some role in more precisely defin-
ing the appropriate duration of anticoagulation in indi-
vidual patients. The relationship between persistently
elevated D-dimer and F 1+2 levels and thrombotic risk
factors tends to support current recommendations
that patients with irreversible thrombotic risk factors
warrant a longer duration of anticoagulation. Such
measurements could also conceivably be useful in
identifying those patients with idiopathic DVT at
highest risk for recurrence and requiring extended
anticoagulation. Validation of such speculation would
obviously require larger series examining the relation-
ship between these markers at the completion of a
standard course of anticoagulation and the incidence
of late recurrent events.
It is important to recognize the shortcomings of
this study, most notably the small number of patients.
The number of patients in some subgroups, such as
those having specific risk factors with late recurrence,
was quite small. It is certainly possible that important
relationships between risk factors, D-dimer and F
1+2 levels, and recurrent thrombosis were over-
looked. Furthermore, although consecutive patients
meeting entry criteria were enrolled, and the ultra-
sound scans and laboratory tests were independently
interpreted, this was an exploratory study not
designed primarily to document the diagnostic accu-
racy of these markers. Neither was it designed as a
management trial to evaluate the use of these mark-
ers in clinical decision making. It is also important to
note that quantitative ELISA assays were used in this
study and that the results may not be applicable to
semiquantitative latex and hemagglutination tests.
Finally, a standardized treatment regimen was not
used in this study. Although D-dimer levels were
independent of initial treatment, early F 1+2 levels
were significantly related to anticoagulation with
unfractionated or low-molecular-weight heparin.
Although unlikely to change the D-dimer results,
anticoagulation of the 26.3% of patients who were
not initially treated could alter the time course of F
1+2 levels, potentially making this marker more suit-
able for the diagnosis of recurrent thrombotic events.
Despite these limitations, this study further
defines the evolution of stable markers of activated
coagulation and fibrinolysis after an episode of acute
DVT. Initial F 1+2 levels are most significantly associ-
ated with the presence of proximal thrombus, where-
as D-dimer levels reflect the extent of thrombus and
perhaps individual differences in the fibrinolytic sys-
tem. Initial levels of both markers are predictive of
recurrent thrombotic events. This observation may
have particular relevance to the treatment of isolated
calf vein thrombosis and warrants further investiga-
tion. Although levels of both markers rapidly decline
after presentation, they remain elevated in a substan-
tial number of patients for at least 1 year. This limits
the specificity and positive predictive value of these
markers in recurrent DVT, although they appear to
have some utility in excluding the diagnosis.
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DISCUSSION
Dr Thomas W. Wakefield (Ann Arbor, Mich). Dr
Meissner and coworkers continue their excellent studies
on venous thrombosis, and this is really a nicely done
study and the manuscript is very scholarly. 
The current work suggests that measurements of D-
dimer were significantly elevated in patients who suffered
DVT, with thrombus score predicting initial D-dimer lev-
els, while F 1+2 levels were also elevated with the presence
of proximal thrombus the only significant predictor of F
1+2 levels. One year after thrombosis D-dimer and F 1+2
levels remained elevated in 70% and 35% of patients, how-
ever, which necessitated a change in the values noted
important for defining recurrent DVT. Importantly, initial
levels of D-dimer greater than 2000 ng/mL and F 1+2
greater than 2 nmol/L carried greater than 80% sensitivity
for the diagnosis of recurrent DVT. This is key, as we know
from other data in the literature that one of the most
important factors in the development of chronic venous
insufficiency is the presence of ipsilateral recurrent DVT. 
I am going to ask two questions. First, can you specu-
late on the cause of the persistent elevations in D-dimer and
F 1+2 levels at 1 year after DVT formation? I can certainly
understand that persistent F 1+2 levels might indicate a
baseline prothrombotic state, but D-dimer levels should
reflect the breakdown of formed thrombus. We know that
after 10 days to 2 weeks, thrombus inside of veins turns to
scar tissue. With this in mind, where is the D-dimer coming
from at these later follow-up time points? In fact, you show
levels of D-dimer increased at 9 months and 1 year com-
pared with the 6-month time point in your study.
Secondly, can you make some comments concerning
the type of D-dimer assay used in your study compared
with the rapid bedside D-dimer assays that are on the mar-
ket today? Would your data change or remain the same
using a simple rapid bedside test?
I congratulate the authors on a fine piece of work and
thank the American Venous Forum for the opportunity to
discuss this paper.
Dr Mark Meissner. Thank you, Dr Wakefield. With
respect to your question regarding the late D-dimer eleva-
tions I think you are exactly right. As you can see from the
graph, D-dimer levels declined rapidly initially, which like-
ly reflects a decrease in generation of new lysable fibrin.
With the absence of new lysable fibrin, D-dimer levels
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plateau. I think it is most important to note that the F 1+2
levels stayed elevated in a substantial number of patients
and that there was likely ongoing fibrin generation in
these patients accounting for the persistently elevated D-
dimer levels. I would propose, although I have no data to
prove it, that the D-dimer levels late during follow-up
result from the generation of new thrombin that is the
result of the elevated F 1+2 levels. 
Regarding the assay used in this study, this was a quan-
titative assay, which as most people are aware, is a long test
requiring approximately 4 hours to perform. For research
purposes, the tests were run in batches. The sensitivity and
specificity levels and our cutoff level of 400 were based on
the assay we use clinically, which is a rapid ELISA test that
returns results within 1 hour. Based on the literature, these
results are probably applicable to rapid ELISA tests. I
think they are probably not applicable to latex agglutina-
tion tests, which I do not think have similar sensitivity and
specificity at the levels used in this study.
Thank you very much.
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